The Relative Strength (RS) Rating for Repligen entered a new percentile Tuesday, as it got a lift from 70 to 76.
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest price moves. See if Repligen can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
While now is not an ideal time to jump in, see if the stock manages to offer and clear a proper buy point.
Earnings grew 87% last quarter, up from -24% in the prior report. Revenue also increased, from -3% to 10%. The company is expected to report its latest numbers on or around Feb. 19.
The company earns the No. 8 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology, Veracyte and Natera are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
